Stellar Biotechnologies Inc (SBOT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Stellar Biotechnologies Inc (SBOT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8155
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injectable product to assess immune response. Its products comprise Stellar KLH protein which can be used in various grades, formulations, and configurations for both clinical and research applications and KLH Elisa Kits. Stellar Bio’s products are used in immunotherapies as an immune stimulant in immunotoxicology applications and therapeutic vaccine conjugation. The company partners with research centers and developers of active immunotherapies and therapeutic vaccines. Stellar Bio is headquartered in Port Hueneme, California, the US.

Stellar Biotechnologies Inc (SBOT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Stellar Biotech and Neovacs Form Joint Venture 12
Stellar Biotech Enters Into Co-Development Agreement With Amaran Biotech 13
Equity Offering 14
Stellar Biotech to Raise USD3 Million in Private Placement of Shares up on Exercise of Warrants 14
Stellar Biotech Raises USD5.5 Million in Public Offering of Units 15
Stellar Biotech Raises USD6.8 Million in Private Placement of Shares and Warrants 16
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 17
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 19
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 21
Stellar Biotech Completes Private Placement Of Units For US$0.5 Million 22
Stellar Biotechnologies Completes Private Placement Of Units For US$1 Million 23
Asset Transactions 24
Matrivax to Acquire Immunogen and Vaccine Technology from Stellar Biotech 24
Stellar Biotechnologies Inc – Key Competitors 25
Stellar Biotechnologies Inc – Key Employees 26
Stellar Biotechnologies Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Joint Venture 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Stellar Biotechnologies reports third quarter financial results 28
May 07, 2018: Stellar Biotechnologies Announces Second Quarter Financial Results 30
Feb 07, 2018: Stellar Biotechnologies Reports First Quarter 2018 Financial Results 32
Dec 01, 2017: Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results 33
Aug 09, 2017: Stellar Biotechnologies Reports Third Quarter 2017 Financial Results 34
May 09, 2017: Stellar Biotechnologies Reports Second Quarter 2017 Financial Results 36
Feb 06, 2017: Stellar Biotechnologies Reports First Quarter 2017 Financial Results 38
Corporate Communications 39
Jan 25, 2018: Stellar Biotechnologies Appoints Pharma Licensing Expert to Board of Directors 39
Product News 40
Jun 21, 2018: Stellar Reports Positive Research Results from KLH Glycosylation Study 40
Jan 11, 2017: Stellar Biotechnologies Advances Strategic Plan to Secure Key Production Region 41
Other Significant Developments 42
May 24, 2018: Stellar Achieves Robust Viral Clearance for Manufacturing Process 42
Mar 29, 2018: Stellar Biotech Begins Scale-Up and Expansion Project at Port Facility 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stellar Biotechnologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Stellar Biotech and Neovacs Form Joint Venture 12
Stellar Biotech Enters Into Co-Development Agreement With Amaran Biotech 13
Stellar Biotech to Raise USD3 Million in Private Placement of Shares up on Exercise of Warrants 14
Stellar Biotech Raises USD5.5 Million in Public Offering of Units 15
Stellar Biotech Raises USD6.8 Million in Private Placement of Shares and Warrants 16
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 17
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 19
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 21
Stellar Biotech Completes Private Placement Of Units For US$0.5 Million 22
Stellar Biotechnologies Completes Private Placement Of Units For US$1 Million 23
Matrivax to Acquire Immunogen and Vaccine Technology from Stellar Biotech 24
Stellar Biotechnologies Inc, Key Competitors 25
Stellar Biotechnologies Inc, Key Employees 26
Stellar Biotechnologies Inc, Subsidiaries 27
Stellar Biotechnologies Inc, Joint Venture 27

List of Figures
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Stellar Biotechnologies Inc (SBOT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SRI International-医療機器分野:企業M&A・提携分析
    Summary SRI International (SRI) is a research institute which provides commercial research and development programs. It conducts research and development in the areas of biosciences, health and medical systems, chemistry and materials, communications and networks, computing, earth and space, economi …
  • Waste Management Inc (WM):企業の財務・戦略的SWOT分析
    Waste Management Inc (WM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Catabasis Pharmaceuticals Inc (CATB):企業の財務・戦略的SWOT分析
    Summary Catabasis Pharmaceuticals Inc (Catabasis Pharmaceuticals) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes medicines for the treatment of multiple diseases. The company develops its product candidates using its proprietary safely metabolized and ratio …
  • Barry Callebaut AG:企業のM&A・事業提携・投資動向
    Barry Callebaut AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Barry Callebaut AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • BASF Corp-エネルギー分野:企業M&A・提携分析
    Summary BASF Corp (BASF), a subsidiary of BASF SE, is a chemical manufacturing company. Its product portfolio includes petrochemicals, monomers, intermediates, dispersions and pigments, care chemicals, nutrition and health products, paper chemicals, performance chemicals, catalysts, construction che …
  • ALFA, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    ALFA, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary ALFA, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Theradex Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Theradex Systems Inc (Theradex) is a research organization that provides clinical trials monitoring services. The organization develops medical devices, pharmaceutical compounds and diagnostic tests in the areas of oncology and life-threatening diseases. It provides services such as clinical …
  • Colt Technology Services Group Ltd:企業の戦略的SWOT分析
    Colt Technology Services Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Sellier & Bellot J.S.C.:企業の戦略・SWOT・財務情報
    Sellier & Bellot J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Sellier & Bellot J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Tyson Foods Inc:企業のM&A・事業提携・投資動向
    Tyson Foods Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tyson Foods Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Windtree Therapeutics Inc (WINT):医療機器:M&Aディール及び事業提携情報
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …
  • PetroMaroc Corporation Plc (PMA):企業の財務・戦略的SWOT分析
    Summary PetroMaroc Corporation Plc (Petromaroc), formerly Longreach Oil and Gas Ltd, is an oil and gas exploration and development company that evaluates, acquires, explores and develops oil and gas properties in Morocco. The company holds interests in the Sidi Moktar licence area which includes geo …
  • Holland Colours NV (HOLCO):企業の財務・戦略的SWOT分析
    Holland Colours NV (HOLCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Maire Tecnimont SpA (MT):企業の財務・戦略的SWOT分析
    Maire Tecnimont SpA (MT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • China National Biotec Group-製薬・医療分野:企業M&A・提携分析
    Summary China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corp is a manufacturer and distributor of vaccines, therapeutic products and diagnostic reagents. The company develops biological products for disease prevention, therapeutic and diagnostic use. Its produ …
  • Core-Mark Holding Company, Inc. (CORE):企業の財務・戦略的SWOT分析
    Core-Mark Holding Company, Inc. (CORE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • PetroRio SA (PRIO3):石油・ガス:M&Aディール及び事業提携情報
    Summary PetroRio SA (PetroRio), formerly HRT Participacoes em Petroleo SA, a subsidiary of HRT Oil & Gas Ltd, is oil and gas company that offers investment and recovering of oil production assets. The company offers development of solid growth platforms aiming to generate value to its shareholders b …
  • Trellis Bioscience Inc-製薬・医療分野:企業M&A・提携分析
    Summary Trellis Bioscience Inc (Trellis) is a healthcare services provider that offers therapies. The company discovers and develops human antibody therapeutics for the treatment of infectious diseases and cancer indications. It provides technology to defeat the deficiencies of current screening met …
  • Nitto Denko Corp (6988):製薬・医療:M&Aディール及び事業提携情報
    Summary Nitto Denko Corp (Nitto) is a manufacturer of diversified material, which produces electrical insulating material, electronics, industrial and functional products by harnessing its core technologies such as polymer synthesis, and adhesive and coating technologies. The company offers a broad …
  • Future Plc (FUTR):企業の財務・戦略的SWOT分析
    Summary Future Plc (Future) is a media company that offers media and digital business solutions various customers. The company offers its services in various areas such as technology, creative, photography and design, games, advertising and film and music. It provides licensing and syndication, expo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆